Keloids are more than just cosmetic nuisances they can be painful, itchy, and emotionally distressing. Defined as abnormal, fibrotic scars that extend beyond the boundaries of the original wound, keloid formation affects millions worldwide, particularly individuals with darker skin tones. Unlike typical scars, keloids grow excessively due to an overactive wound-healing response. While their exact cause remains elusive, recent research has shed light on the genetic underpinnings, triggering factors, and emerging treatments that are changing how dermatologists approach this challenging condition.

What Are Keloids?

A keloid is a type of hypertrophic scar, but it is distinguished by its ability to invade surrounding healthy tissue and persist long after healing. They appear as raised, firm, often shiny lesions, typically on the chest, shoulders, earlobes, jawline, and upper back. Unlike hypertrophic scars, which may regress over time, keloids tend to grow over months to years, rarely resolving on their own (Berman & Bieley, 1995).

The Genetics of Keloid Formation

Genetics play a pivotal role in determining who is susceptible to keloids. Studies have shown that individuals of African, Asian, and Hispanic descent are more likely to develop keloids, suggesting a strong hereditary component.

  • Family history increases the risk significantly, indicating autosomal dominant inheritance with incomplete penetrance (Marneros et al., 2001).
  • Genetic polymorphisms in genes like TGF-β1, p53, and SMAD2/3 have been associated with altered wound healing and fibrosis (Shih & Bayat, 2010).
  • Abnormal fibroblast activity in keloid-prone individuals leads to excessive collagen types I and III deposition and reduced collagen degradation.

Understanding these genetic factors opens the door to targeted therapies that interrupt the molecular signaling pathways involved in fibrotic scarring.

Common Triggers and Risk Factors

Even in genetically predisposed individuals, certain environmental or physiological factors often trigger keloid formation, including:

  • Skin trauma: Cuts, piercings, acne, burns, and surgical incisions are frequent culprits.
  • Inflammation: Acne or folliculitis can lead to keloids, particularly on the jawline or chest.
  • Tension-prone areas: Keloids commonly form where the skin is under mechanical stress, such as over joints or on the chest.
  • Hormonal changes: Keloids often worsen during puberty or pregnancy, suggesting hormonal influence.

Importantly, not everyone with these triggers will develop keloids, which further highlights the complex interplay between genetics and environment.

Traditional Treatments and Limitations

Managing keloids is notoriously difficult due to their high recurrence rate and unpredictable response to treatment. Traditional approaches include:

  • Intralesional corticosteroid injections: These remain the first-line treatment, often using triamcinolone to reduce inflammation and flatten the scar. However, recurrence is common without adjunctive therapy.
  • Surgical excision: Removing a keloid surgically can ironically stimulate further growth unless combined with radiation or other therapies.
  • Cryotherapy: Freezing the lesion can shrink smaller keloids, especially on earlobes.
  • Silicone gel sheets and pressure therapy: These non-invasive options are used primarily for prevention or in early-stage keloids.

Unfortunately, none of these treatments offer guaranteed or permanent resolution, especially in genetically susceptible individuals.

Emerging and Promising Therapies

The limitations of conventional therapies have led to novel treatment strategies aimed at disrupting the molecular pathways responsible for keloid formation:

1. Botulinum Toxin A

Botox, known for its cosmetic uses, has shown promise in reducing keloid size and improving scar pliability. It is believed to inhibit fibroblast proliferation and TGF-β1 signaling (Zhibo & Miaobo, 2008).

2. Laser Therapy

Fractional CO₂ lasers and pulsed dye lasers are being used to reduce redness and improve texture in keloid scars. When combined with corticosteroids or 5-fluorouracil (5-FU), they may also help reduce recurrence (Manuskiatti et al., 2002).

3. Targeted Molecular Therapies

Antifibrotic agents like imatinib, a tyrosine kinase inhibitor, are being studied for their ability to block PDGF and TGF-β signaling pathways in keloid fibroblasts (Phan et al., 2003).

4. Stem Cell Therapy and Gene Editing

Emerging research is exploring how mesenchymal stem cells and CRISPR-based gene editing can be used to correct or prevent the overexpression of fibrotic genes in at-risk individuals. Though still experimental, this could mark a revolutionary shift in scar therapy.

Prevention: Still the Best Strategy

For individuals with a personal or family history of keloids, prevention remains critical:

  • Avoid unnecessary piercings or elective surgeries in high-risk areas.
  • Treat acne and inflammatory skin conditions early to minimize scarring.
  • Use silicone sheets or pressure earrings after surgeries or piercings.
  • Monitor wounds closely, especially on keloid-prone areas.

Keloid formation is a complex condition influenced by genetic predisposition, environmental triggers, and immune dysregulation. While traditional therapies have offered moderate success, advances in molecular medicine, laser technology, and regenerative therapies are opening new frontiers in treatment. For patients who have long felt defeated by persistent, painful, or disfiguring scars, hope is on the horizon. As our understanding deepens, personalized, effective, and lasting keloid solutions are becoming a more achievable reality.

References

  1. Berman, B., & Bieley, H. C. (1995). Keloids. Journal of the American Academy of Dermatology, 33(1), 117–123. https://doi.org/10.1016/0190-9622(95)90188-4
  2. Marneros, A. G., Norris, J. E., Watanabe, S., Reichenberger, E., & Olsen, B. R. (2001). Clinical genetics of familial keloids. Archives of Dermatology, 137(11), 1429–1434. https://doi.org/10.1001/archderm.137.11.1429
  3. Shih, B., & Bayat, A. (2010). Genetics of keloid scarring. Archives of Dermatological Research, 302(5), 319–339. https://doi.org/10.1007/s00403-010-1057-0
  4. Zhibo, X., & Miaobo, Z. (2008). Botulinum toxin type A affects transforming growth factor β1 expression in fibroblasts derived from hypertrophic scar. Aesthetic Plastic Surgery, 32(4), 574–580. https://doi.org/10.1007/s00266-008-9146-5
  5. Manuskiatti, W., Fitzpatrick, R. E., & Goldman, M. P. (2002). Long-pulsed Nd:YAG laser treatment of keloids and hypertrophic scars. Lasers in Surgery and Medicine, 30(2), 112–117. https://doi.org/10.1002/lsm.10013
  6. Phan, T. T., Lim, I. J., Aalami, O., Lorenz, H. P., & Longaker, M. T. (2003). Imatinib mesylate, a tyrosine kinase inhibitor, inhibits keloid fibroblast proliferation and collagen production. Plastic and Reconstructive Surgery, 111(5), 1638–1645. https://doi.org/10.1097/01.PRS.0000055795.33769.95

RELATED ARTICLESMORE FROM AUTHOR